Thus, we postulate that joint activation of TGR5 and FXR would (1) provide more protection against NASH and associated dysmetabolic features and (2) limit the side effects observed by selective agonists. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatohepatitis.